Clinical Events Independent Assessment and Adjudication is crucial for reducing patients’ risks and bias related with multi center studies with subjective or image-based endpoints.
The Endpoint Adjudication in Clinical Trials group is aimed at growing knowledge and building a Professional Community of Clinical Research Professionals working with Clinical Endpoints / Imaging Independent Review & Adjudication.
By joining this group, you can share, discuss about and contribute with your own opinions to this Knowledge Base built on Regulations, Literature, Events, Procedures and Tools about the Independent Review & Adjudication process as used in Clinical Trials.
By joining this group, you can support and contribute with your own opinions and experiences and also keep yourself updated about Endpoint Adjudication related Regulations, Literature, Events, Procedures, and Tools.
Here some samples of most appreciated posts:
------------------
Endpoint Adjudication Methods used in Clinical Trials for 69% of the NMEs approved by FDA and 41% by EMA
https://www.linkedin.com/groups/8177210/8177210-5998731741286715392
------------------
Karen A. Hicks (FDA): Considerations for Endpoint Adjudication Committees
https://www.linkedin.com/groups/8177210/8177210-6006066962797522948
------------------
Beat Widler: A p-Value is only as Good as the Data.
https://www.linkedin.com/groups/8177210/8177210-6039331989562077186
------------------
Endpoint Adjudication Survey Reveals Cultural Challenges and Lacking Regulatory Guidance
https://www.linkedin.com/groups/8177210/8177210-6084629511494787075
------------------
Endpoint Adjudication of Events Charter Template: What Should Be Included?
https://www.linkedin.com/groups/8177210/8177210-6214712901291245572
------------------
So my "calls to action" are:
- SHARE YOUR EXPERTISE
- ASK or GIVE HELP
- DISCUSS ANY ISSUES
- SUPPORT GROUP NETWORKING
Please contact /connect with me for any further help: mimmo.garibbo@ethical.ch
NOTE: Advertising Posts will be deleted.
